Should I buy Sabra Health Care REIT (SBRA) stock or is it too late?
⭐ The most reliable of them, either direction: Baird — 64% of its targets hit on this sector (55 calls tested). It aims for $23 (+11 %), call made on July 23, 2026, maturing on July 23, 2027 (36 d ago).
Firm-by-firm track record on Sabra Health Care REIT
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Jefferies | 80 % | +14.0 % | 10 | $15 -28% |
| Stifel | 65 % | +8.4 % | 17 | $16 -23% |
| Mizuho | 43 % | -4.6 % | 7 | $20 -3% |
| JMP Securities | 50 % | -6.4 % | 8 | $22 +6% |
| Barclays | 38 % | -9.2 % | 8 | $21 +1% |
| B of A Securities | 33 % | -1.7 % | 6 | — |
✅ Reasons to believe
- Pays a dividend (6.1% yield) — regular income on top of potential upside.
⚠️ Reasons to hesitate
- Even the most reliable firm on SBRA, Citigroup (100% hit rate, 2 scored calls), only targets $19 (call made on June 23, 2026, maturing on June 23, 2027) (-8%) in its most recent call, and $24 (call made on February 18, 2026, maturing on February 18, 2027) (+16%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 10 ratings, 7 are neutral.
- Limited upside: the median target is only +6% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on SBRA
Median target $22 (+6%) · 10 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Sabra Health Care REIT now?
We won't decide for you. The facts: 30% of analysts rate it a buy, median target $22 (+6%), and Citigroup (most reliable on SBRA, 100%) targets $19. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Sabra Health Care REIT?
Not according to analysts: the median target ($22) is still +6% above the current price ($21) (most reliable on SBRA: Citigroup, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Sabra Health Care REIT still worth investing in?
It depends on the gap between the price ($21) and its estimated value: analysts target $22 on median (+6%), with 30% buys (most reliable on SBRA: Citigroup, 100%). Cross-check with their real reliability on SBRA and the cautions above. Information, not advice.
What's the main risk in buying SBRA?
Even the most reliable firm on SBRA, Citigroup (100% hit rate, 2 scored calls), only targets $19 (call made on June 23, 2026, maturing on June 23, 2027) (-8%) in its most recent call, and $24 (call made on February 18, 2026, maturing on February 18, 2027) (+16%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Sabra Health Care REIT profile (consensus, analyst reliability, price target, performance).